Intranasal Coronavirus SARS-CoV-2 Immunization with Lipid Adjuvants Provides Systemic and Mucosal Immune Response against SARS-CoV-2 S1 Spike and Nucleocapsid Protein

In this preclinical two-dose mucosal immunization study, using a combination of S1 spike and nucleocapsid proteins with cationic (N3)/or anionic (L3) lipids were investigated using an intranasal delivery route. The study showed that nasal administration of low amounts of antigens/adjuvants induced a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sengupta, Anirban, Azharuddin, Mohammad, Cardona, Maria E., Devito, Claudia, von Castelmur, Eleanore, Wehlin, Anna, Pietras, Zuzanna, Sunnerhagen, Maria, Selegård, Robert, Aili, Daniel, Alamer, Ali, Hinkula, Jorma, Al-Otaibi, Noha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029453/
https://www.ncbi.nlm.nih.gov/pubmed/35455253
http://dx.doi.org/10.3390/vaccines10040504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029453/
https://www.ncbi.nlm.nih.gov/pubmed/35455253
http://dx.doi.org/10.3390/vaccines10040504

Ejemplares similares